

### **REMARKS**

The office action mailed June 3, 2009, requests a particular species of alpha v-integrin antagonist to be elected. Moreover, the office action requests an election of a specific treatment method. In response to these requirements, Applicants elect treatment of secondary biliary liver fibrosis, and elect 3-{3Benzyloxy-2-[5-(pyridine-2-ylamino)-pentanoylamino]-propanoylamino}-3-(3, 5-dichloro-phenyl)-propionic acid.

In light of the foregoing elections, the claims have been amended, and new claim 10, the only existing claim, is directed to the elected species.

A prompt action on the merits is accordingly respectfully requested. Should the Examiner have any questions or comments, he is cordially invited to telephone the undersigned at the number below.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/Harry B. Shubin/

---

Harry B. Shubin, Reg. No. 32,004  
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3151

Date: July 6, 2009  
HBS/tls